Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer (ABC)
This study is currently recruiting participants.
Verified December 2012 by Duke University
Sponsor:
Duke University
Collaborators:
Genentech
Celgene Corporation
Information provided by (Responsible Party):
Duke University
ClinicalTrials.gov Identifier:
NCT00479674
First received: May 25, 2007
Last updated: December 28, 2012
Last verified: December 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | May 2016 |
| Estimated Primary Completion Date: | May 2014 (Final data collection date for primary outcome measure) |